<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan D Reed, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Renata R Urban, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rochelle L Garcia, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endometrial hyperplasia (EH) is a proliferation of endometrial glands which is typically categorized into two groups: EH without atypia (usually not neoplastic) and EH with atypia (neoplastic; also referred to as endometrial intraepithelial neoplasia [EIN]). EH, especially EH with atypia, is of clinical significance because it may progress to, or coexist with, endometrial carcinoma.
        </p>
        <p>
         The clinical features, diagnosis, and differential diagnosis of EH are presented here. Management of EH, as well as other related topics, is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of EH (see
         <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">
          "Endometrial hyperplasia: Management and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other etiologies of abnormal uterine bleeding (see
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5421.html" rel="external">
          "Approach to the patient with postmenopausal uterine bleeding"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endometrial carcinoma (see
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">
          "Endometrial carcinoma: Epidemiology, risk factors, and prevention"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1332404108">
         <span class="h1">
          CLASSIFICATION AND HISTOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2292938030">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The terminology and classification systems for EH have changed significantly over time  (
         <a class="graphic graphic_table graphicRef115177" href="/z/d/graphic/115177.html" rel="external">
          table 1
         </a>
         ). The two main classification systems for EH are the 2014 World Health Organization (WHO) system and the endometrial intraepithelial neoplasia (EIN) system [
         <a href="#rid1">
          1,2
         </a>
         ]. The 2014 WHO system is more widely used [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         This topic will utilize the 2014 WHO classification system. However, supporting studies cited in this topic may use other classification systems, which will be documented where appropriate.
        </p>
        <p>
         Few studies have compared the diagnostic performance of the WHO and EIN systems; in addition, such studies utilized the 1994, rather than the 2014, WHO classification system [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H506961">
         <span class="h2">
          World Health Organization classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2014 WHO classification system includes the following categories [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal endometrium
         </strong>
         – During the normal menstrual cycle, the endometrium is proliferative in the follicular phase and is secretory in the luteal phase  (
         <a class="graphic graphic_figure graphicRef62189" href="/z/d/graphic/62189.html" rel="external">
          figure 1
         </a>
         ). Normal proliferative endometrium exhibits no crowding of glands within the stroma (gland-to-stroma ratio &lt;2:1)  (
         <a class="graphic graphic_picture graphicRef67488" href="/z/d/graphic/67488.html" rel="external">
          picture 1
         </a>
         ). Normal secretory endometrium may have a gland-to-stroma ratio of &gt;2:1  (
         <a class="graphic graphic_picture graphicRef76588" href="/z/d/graphic/76588.html" rel="external">
          picture 2
         </a>
         ). Although glands in the secretory phase exhibit crowding, they are organized, and cells comprising the glands are spaced and not mitotically active.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperplasia without atypia
         </strong>
         – This term was previously referred to as simple or complex hyperplasia without atypia [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In EH without atypia, the gland-to-stroma ratio is increased (gland-to-stroma ratio &gt;2:1); the glands may be mildly crowded, dilated, and have luminal outpouching  (
         <a class="graphic graphic_picture graphicRef140424" href="/z/d/graphic/140424.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, atypical nuclear features are not present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical hyperplasia
         </strong>
         (hyperplasia with atypia; EIN) – This term was previously referred to as simple or complex hyperplasia with atypia [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In EH with atypia, the gland-to-stroma ratio is increased further, and there is a disorganization of glands with luminal outpouching, cellular mitoses, and nuclear atypia  (
         <a class="graphic graphic_picture graphicRef140425" href="/z/d/graphic/140425.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. The chromatin may be either evenly dispersed or clumped, and/or prominent nucleoli may be present [
         <a href="#rid8">
          8,9
         </a>
         ]. Rarely, extreme complexity without marked cytologic atypia warrants a diagnosis of EH with atypia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The finding of nuclear atypia has relatively poor interobserver agreement [
         <a href="#rid10">
          10-16
         </a>
         ]. This is discussed in more detail below. (See
         <a class="local">
          'Subsequent evaluation of EH with atypia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         This classification system is intended to reduce the confusion associated with numerous pathologic terms (eg, simple or complex, with or without atypia) and also to reflect that hyperplasia without atypia is typically a nonneoplastic change whereas hyperplasia with atypia is neoplastic and frequently associated with endometrial carcinoma [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Endometrial intraepithelial neoplasia classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The EIN classification system was proposed by an international group of gynecologic pathologists in 2000 [
         <a href="#rid2">
          2
         </a>
         ]. EIN classification categories do not correspond directly to specific categories in the 2014 WHO system, but there is some overlap  (
         <a class="graphic graphic_table graphicRef115177" href="/z/d/graphic/115177.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The EIN system has been slow to gain widespread acceptance, most likely due to cost and/or lack of experience with the computerized D-scoring component, which is an integral part of the EIN classification system and described briefly below [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
         The EIN system defines two classes of endometrial changes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign endometrial hyperplasia
         </strong>
         (nonneoplastic) – This group represents changes typically observed with anovulation or prolonged exposure to estrogen. The morphology of benign EH varies from proliferative endometrium with scattered cysts [
         <a href="#rid21">
          21
         </a>
         ] (persistent proliferative endometrium) to bulkier endometrium with many dilated and contorted glands that in other systems have been designated as "cystic glandular hyperplasia," "mild hyperplasia," or "simple hyperplasia."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endometrial intraepithelial neoplasia
         </strong>
         (EIN) – This group represents premalignant lesions on the endometrium. Epithelial glandular crowding displaces stroma to a point at which stromal volume is less than approximately one-half of total tissue volume in nonsecretory endometrium, and typically, cells appear morphologically clonal and distinct from the surrounding endometrium.
        </p>
        <p>
        </p>
        <p>
         The computerized D-scoring component is a measure of stromal volume as a proportion of total tissue volume (stroma + epithelium + gland lumen). Using this method, specimens are classified as benign (D &gt;1), indeterminate (D between 0 and 1), or EIN (D &lt;0). The D-score is assigned based on evaluation with computerized morphometry. A potential alternative to computerized morphometry is subjective EIN classification. This approach appeared to correlate well with estimates using the computerized D-score in one small study including 84 patients of whom 10 percent (8 patients) developed cancer [
         <a href="#rid22">
          22
         </a>
         ]. However, more experience is needed to evaluate subjective assignment of the D-score in diverse practice environments.
        </p>
        <p>
         As with the WHO classification system, the EIN classification system also has demonstrated moderate interobserver reproducibility [
         <a href="#rid23">
          23
         </a>
         ], but studies have confirmed that EIN correlates with progression to endometrial carcinoma [
         <a href="#rid19">
          19,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H507038">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reliable estimates of the incidence of EH are difficult to obtain due to many factors, including age and menopausal status of patients studied, changing diagnostic criteria over time, bias of studies toward evaluating only symptomatic patients (eg, abnormal uterine bleeding), trends in postmenopausal hormone therapy (eg, the use of unopposed estrogen versus estrogen plus progestin), assessment technique (eg, endometrial sampling versus hysterectomy), and concomitant diagnoses of endometrial carcinoma with hyperplasia. (See
         <a class="local">
          'Natural history'
         </a>
         below.)
        </p>
        <p>
         EH is most common in perimenopausal or early postmenopausal patients. Representative studies include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study including females ages 18 to 90 from a large integrated health plan over an 18-year period (1985 to 2003), the overall incidence of EH was 133 per 100,000 woman-years [
         <a href="#rid25">
          25
         </a>
         ]. The incidence of EH without atypia was highest in patients ages 50 to 54 years (between 142 and 213 per 100,000 woman-years) whereas the rate of EH with atypia was highest in patients ages 60 to 64 (56 per 100,000 woman-years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An analysis from another large health plan found that the rate of EH was 144 per 100,000 woman-years in 2002 [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for EH are similar to those for endometrial carcinoma  (
         <a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
         Most of these risk factors involve exposure of the endometrium to continuous estrogen unopposed by progestin. This effect may be due to an endogenous (eg, obesity, ovulatory dysfunction) or exogenous (eg, medications, including nonprescription and topical therapies) source of estrogen. By contrast, patients with menstrual irregularities caused by hypothalamic hypogonadism (and low serum concentrations of luteinizing hormone [LH], follicle-stimulating hormone [FSH], and estradiol) are not at increased risk of EH.
        </p>
        <p>
         Patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) or Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome) are at a greatly increased risk of EH and endometrial carcinoma.
        </p>
        <p>
         These risk factors are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">
          "Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer", section on 'Risk for endometrial cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Genitourinary'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1979570397">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1862088566">
         <span class="h2">
          Presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         EH typically presents with abnormal uterine bleeding. Less commonly, EH presents with the following  (
         <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal cytologic findings on cervical cancer screening (eg, atypical glandular cells, benign endometrial cells in a patient ≥45 years) [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">
          "Cervical cancer screening: The cytology and human papillomavirus report", section on 'Benign-appearing endometrial cells'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3229.html" rel="external">
          "Cervical cytology: Evaluation of atypical and malignant glandular cells", section on 'Risk of premalignant or malignant disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A postmenopausal patient with a thickened endometrial stripe on imaging. (See
         <a class="local">
          'Findings'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incidental finding during hysterectomy for another indication.
        </p>
        <p>
        </p>
        <p>
         The presentation of EH and endometrial carcinoma is similar and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H508097">
         <span class="h2">
          Findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical findings of EH are similar to those of patients with endometrial carcinoma.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pelvic examination
         </strong>
         – Pelvic examination is usually normal since patients with EH do not typically have an enlarged or tender uterus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory results
         </strong>
         – Laboratory results are usually normal, except in patients with substantial abnormal uterine bleeding who may be anemic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – In postmenopausal patients, ultrasound may demonstrate an increased endometrial thickness with multiple cystic features and heterogeneity [
         <a href="#rid31">
          31
         </a>
         ]; however, ultrasound criteria have not been set for the detection of EH as they have for endometrial carcinoma. Thus, endometrial thickness in a postmenopausal patient in the absence of bleeding is a nonspecific finding, but one that requires further evaluation for EH [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">
          "Overview of the evaluation of the endometrium for malignant or premalignant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These findings are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Clinical findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2120715973">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         EH may progress to, or coexist with, endometrial carcinoma.
        </p>
        <p>
         The risk of progression of EH to endometrial cancer is almost fourfold higher for patients with EH with atypia (endometrial intraepithelial neoplasia [EIN]) compared with EH without atypia [
         <a href="#rid33">
          33
         </a>
         ]; this is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">
          "Endometrial hyperplasia: Management and prognosis", section on 'EH with atypia (EIN)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">
          "Endometrial hyperplasia: Management and prognosis", section on 'Eh without atypia'
         </a>
         .)
        </p>
        <p>
         Coexistent endometrial carcinoma may be present in up to 40 percent of patients with EH with atypia (EIN) and &lt;1 percent of patients with EH without atypia [
         <a href="#rid1">
          1,5,10,11,34
         </a>
         ]. Among patients with EH, the strongest predictors of concurrent endometrial carcinoma include older age, obesity, diabetes mellitus, and the finding of atypia on endometrial pathology [
         <a href="#rid35">
          35
         </a>
         ]. In one meta-analysis including 15 retrospective studies and almost 1500 patients with EH, the overall pooled proportion of concurrent endometrial carcinoma (diagnosed within three months of EH diagnosis) was 32 percent (95% CI 26-40 percent) but with a high heterogeneity in the outcomes [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H507663">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EH is a histologic diagnosis based on characteristic findings on endometrial biopsy, dilation and curettage (D&amp;C), or hysterectomy specimen. (See
         <a class="local">
          'Classification and histology'
         </a>
         above.)
        </p>
        <p>
         The procedure for endometrial sampling is discussed in detail separately. (See
         <a class="local">
          'World Health Organization classification'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">
          "Endometrial sampling procedures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">
          "Overview of the evaluation of the endometrium for malignant or premalignant disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3151226207">
         <span class="h2">
          Role of biomarkers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunohistochemical markers may help distinguish EH with atypia (EIN) from EH without atypia or endometrial carcinoma [
         <a href="#rid4">
          4,37-42
         </a>
         ]; however, these biomarkers are investigational and not routinely performed.
        </p>
        <p>
         Such biomarkers include the absence of paired box gene 2 (
         <em>
          PAX2
         </em>
         ) staining [
         <a href="#rid39">
          39-41
         </a>
         ], increased staining for matrix metalloproteinase 9 (MMP-9) and B-cell lymphoma 2 (Bcl-2) [
         <a href="#rid37">
          37,42
         </a>
         ], and estrogen and progesterone overexpression [
         <a href="#rid42">
          42
         </a>
         ]. Other serum biomarkers have also been described [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1166678594">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes endometrial carcinoma, which is distinguished from EH by the presence of invasion on histologic specimen; however, this distinction can be difficult to make unless the uterus is surgically removed and evaluated. (See
         <a class="local">
          'Subsequent evaluation of EH with atypia'
         </a>
         below.)
        </p>
        <p>
         Findings that suggest invasion include an invasive pattern of glands infiltrating reactive stroma (the most definitive), cribriform glands, or confluent growth (lack of stroma between glands). Marked nuclear atypia, especially in the context of atrophic background endometrium, may be present in either EH with atypia (endometrial intraepithelial neoplasia [EIN]) or endometrial carcinoma.
        </p>
        <p>
         The diagnosis of endometrial carcinoma is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4021105383">
         <span class="h1">
          SUBSEQUENT EVALUATION OF EH WITH ATYPIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, for patients with a diagnosis of EH with atypia (endometrial intraepithelial neoplasia [EIN]) made by office endometrial biopsy, we perform a dilation and curettage (D&amp;C) to help exclude a coexisting endometrial carcinoma. (See
         <a class="local">
          'Natural history'
         </a>
         above.)
        </p>
        <p>
         A finding of nuclear atypia has relatively poor interobserver agreement [
         <a href="#rid10">
          10-16
         </a>
         ]. In one study including over 300 endometrial samples initially reported as EH with atypia, review by a panel of expert gynecologic pathologists supported the diagnosis in only 38 percent of cases (correlation coefficient of nuclear atypia 0.28) [
         <a href="#rid14">
          14
         </a>
         ]. In a second study including 289 patients with a diagnosis of complex atypical hyperplasia (ie, EH with atypia), after review by unblinded pathologists (using the 1994 World Health Organization [WHO] criteria), 29 percent were diagnosed with more severe pathology (eg, endometrial carcinoma) [
         <a href="#rid10">
          10
         </a>
         ]. Interobserver variability appears to improve with both increasing specimen volume and presence of prominent nucleoli [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
         Some data suggest that D&amp;C is more effective than endometrial biopsy at detecting coexistent carcinoma, likely due to the volume of the sample obtained [
         <a href="#rid11">
          11,12
         </a>
         ]. However, neither endometrial biopsy nor D&amp;C is sufficient to exclude malignant neoplasm. In one retrospective study including over 820 patients with EH with atypia, the rate of unexpected endometrial carcinoma diagnosed at hysterectomy was higher for patients who underwent a single sampling with endometrial biopsy compared with D&amp;C alone (45 versus 30 percent) [
         <a href="#rid12">
          12
         </a>
         ]. Among patients who had a repeat sampling procedure for confirmation (with either endometrial biopsy or D&amp;C), the rate of unexpected carcinoma at hysterectomy was lower (repeat endometrial biopsy: 20 of 89 patients [22 percent]; endometrial biopsy followed by D&amp;C: 28 of 171 patients [16 percent]). (See
         <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">
          "Endometrial hyperplasia: Management and prognosis", section on 'Hysterectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2870024616">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1447192115">
         <span class="h2">
          Approach to patients with nondiagnostic histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with an endometrial biopsy result that has insufficient endometrial cells and for whom there is a clinical concern for endometrial pathology (ie, EH with or without atypia, endometrial carcinoma) should have sampling repeated with an office biopsy or dilation and curettage (D&amp;C). If two office endometrial biopsies are unsuccessful in providing an adequate sample, a D&amp;C should be performed. Cervical stenosis, a common cause of an unsuccessful biopsy, can be managed with preprocedure cervical preparation (eg,
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ) or dilation. (See
         <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">
          "Endometrial sampling procedures", section on 'Cervical preparation and dilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H76108761">
         <span class="h2">
          Approach to patients with benign histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom bleeding persists or recurs within three to six months after endometrial sampling with benign findings, symptoms may be due to a missed diagnosis of endometrial pathology (ie, EH, endometrial carcinoma), and further evaluation is needed.
        </p>
        <p>
         Reported rates of EH or endometrial carcinoma in patients evaluated for persistent or recurrent postmenopausal bleeding vary widely, from 4 to 22 percent [
         <a href="#rid44">
          44-46
         </a>
         ]. In particular, patients with risk factors for endometrial carcinoma should have repeat sampling  (
         <a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">
          table 2
         </a>
         ). In a nested case-control study of patients with an endometrial carcinoma diagnosis who had previous benign endometrial sampling, a personal history of colorectal cancer, endometrial polyp, and body mass index ≥35 kg/m
         <sup>
          2
         </sup>
         was independently associated with a subsequent diagnosis of endometrial carcinoma [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1441176965">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">
          "Society guideline links: Uterine cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3681758560">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/866.html" rel="external">
          "Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/8401.html" rel="external">
          "Patient education: Abnormal uterine bleeding (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endometrial hyperplasia (EH) is typically categorized into two groups: EH without atypia and EH with atypia (also referred to as endometrial intraepithelial neoplasia [EIN]). EH, particularly EH with atypia, may progress to, or coexist with, endometrial carcinoma. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The 2014 World Health Organization (WHO) classification system is the classification system that is most widely used. The EIN system is another classification system that has been slow to gain widespread acceptance. EIN classification categories do not correspond directly to specific categories in the 2014 WHO system, but there is some overlap  (
         <a class="graphic graphic_table graphicRef115177" href="/z/d/graphic/115177.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Classification and histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – EH commonly results from exposure to continuous estrogen unopposed by a progestin; risk factors are similar to those for endometrial carcinoma  (
         <a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">
          table 2
         </a>
         ). This may be caused by obesity, ovulatory dysfunction, unopposed estrogen therapy, or estrogen-producing ovarian tumors (rare). Patients with Lynch syndrome or Cowden syndrome are at high risk for endometrial neoplasia. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – EH typically presents with abnormal uterine bleeding and is most common in perimenopausal or early postmenopausal patients. Rarely, patients will present with abnormal findings on cervical cytology. (See
         <a class="local">
          'Presentation'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Natural history
         </strong>
         – Coexistent endometrial carcinoma may be present in up to 40 percent of patients who have EH with atypia (EIN). (See
         <a class="local">
          'Natural history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – EH is a histologic diagnosis based on characteristic findings on endometrial biopsy, dilation and curettage (D&amp;C), or hysterectomy specimen. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent evaluation
         </strong>
         – In patients with a diagnosis of EH with atypia made by endometrial biopsy, we perform a D&amp;C to help further evaluate the endometrium and exclude a coexisting endometrial carcinoma. (See
         <a class="local">
          'Subsequent evaluation of EH with atypia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3989112163">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert L Giuntoli, II, MD, and Howard A Zacur, MD, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Emons G, Beckmann MW, Schmidt D, et al. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd 2015; 75:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffone A, Travaglino A, Saccone G, et al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 2019; 299:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanderson PA, Critchley HO, Williams AR, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 2017; 23:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travaglino A, Raffone A, Saccone G, et al. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 2019; 74:676.
          </a>
         </li>
         <li class="breakAll">
          Scully RE, Bonfiglio TA, Kurman, et al. Uterine corpus. In: Histological Typing of Female Genital Tract Tumours, 2nd ed., Springer-Verlag, New York 1994. p.13.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982; 49:2547.
          </a>
         </li>
         <li class="breakAll">
          Mazur MT, Kurman RJ. Endometrial hyperplasia and epithelial cytoplasmic change. In: Diagnosis of Endometrial Biopsies and Curettings. A Practical Approach, Springer-Verlag, New York 1995. p.160.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol 2012; 36:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol 2009; 114:523.
          </a>
         </li>
         <li class="breakAll">
          Hedrick Ellenson L, Ronnett BM, Kurman RJ. Precursor Lesions of Endometrial Carcinoma. In: Blaustein's Pathology of the Female Genital Tract, 6th ed, Kurman RJ, Hedrick Ellenson L, Ronnett, BM (Eds), Springer, New York 2010. p.360-361.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison KH, Reed SD, Voigt LF, et al. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008; 32:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane SE, Hecht JL. Endometrial intraepithelial neoplasia terminology in practice: 4-year experience at a single institution. Int J Gynecol Pathol 2012; 31:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baak JP, Ørbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutter GL, Zaino RJ, Baak JP, et al. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007; 26:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht JL, Ince TA, Baak JP, et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005; 18:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordi J, Bergeron C, Hardisson D, et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology 2014; 64:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacey JV Jr, Mutter GL, Nucci MR, et al. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 2008; 113:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200:678.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacey JV Jr, Chia VM, Rush BB, et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer 2012; 131:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epplein M, Reed SD, Voigt LF, et al. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 2008; 168:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epplein M, Reed SD, Voigt LF, et al. Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy. Ann Epidemiol 2009; 19:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise MR, Gill P, Lensen S, et al. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol 2016; 215:598.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol 2015; 123:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine D, Gupta SC, Kwan C, et al. The Sonographic Appearance of Endometrial Intraepithelial Neoplasia. J Ultrasound Med 2022; 41:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018; 131:e124. Reaffirmed 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010; 116:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semere LG, Ko E, Johnson NR, et al. Endometrial intraepithelial neoplasia: clinical correlates and outcomes. Obstet Gynecol 2011; 118:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuo K, Ramzan AA, Gualtieri MR, et al. Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol 2015; 139:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty MT, Sanni OB, Coleman HG, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One 2020; 15:e0232231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travaglino A, Raffone A, Saccone G, et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosseini Nasab S, Jooya N, Esmaeili A, et al. Using Pyruvate Kinase as a Predictor for Patient With Endometrial Cancer Having Complex Hyperplasia With Atypia to Prevent Hysterectomy and Preserve Fertility: Retrospective Immunohistochemical Study. Reprod Sci 2018; 25:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joiner AK, Quick CM, Jeffus SK. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems. Int J Gynecol Pathol 2015; 34:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quick CM, Laury AR, Monte NM, Mutter GL. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol 2012; 138:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison KH, Upson K, Reed SD, et al. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. Int J Gynecol Pathol 2012; 31:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laas E, Ballester M, Cortez A, et al. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. Gynecol Oncol 2014; 133:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickland AL, Rivera G, Lucas E, et al. PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia. Int J Gynecol Pathol 2019; 38:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twu NF, Chen SS. Five-year follow-up of patients with recurrent postmenopausal bleeding. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003; 188:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012; 120:998.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3217 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25797956" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : New WHO Classification of Endometrial Hyperplasias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10684697" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30810881" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27920066" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : New concepts for an old problem: the diagnosis of endometrial hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30347477" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30347477" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4005805" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7074572" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7074572" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16400639" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23073327" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19701030" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19701030" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16400640" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9706982" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347507" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Diagnosing endometrial hyperplasia: why is it so difficult to agree?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23636398" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Integrated genomic characterization of endometrial carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22317874" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Endometrial intraepithelial neoplasia terminology in practice: 4-year experience at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11420465" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699996" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17413975" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15529181" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24111732" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18720479" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19393600" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Incidence of endometrial hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22290745" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18682485" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064186" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27287687" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25931431" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The Pap test and Bethesda 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34714549" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The Sonographic Appearance of Endometrial Intraepithelial Neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29683909" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20664397" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21691159" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Endometrial intraepithelial neoplasia: clinical correlates and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26238457" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32343732" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30168854" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29153060" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Using Pyruvate Kinase as a Predictor for Patient With Endometrial Cancer Having Complex Hyperplasia With Atypia to Prevent Hysterectomy and Preserve Fertility: Retrospective Immunohistochemical Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25473752" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23086768" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22317873" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556060" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30256235" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969449" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Five-year follow-up of patients with recurrent postmenopausal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20424280" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592247" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090515" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk factors for developing endometrial cancer after benign endometrial sampling.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
